Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NR97: Variant p.Gly572Asp

Toll-like receptor 8
Gene: TLR8
Feedback?
Variant information Variant position: help 572 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Aspartate (D) at position 572 (G572D, p.Gly572Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In IMD98; gain-of-function variant resulting in increased NF-kappa-B activation measured in a reporter assay. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 572 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1041 The length of the canonical sequence.
Location on the sequence: help ELSDLEVLDLSYNSHYFRIA G VTHHLEFIQNFTNLKVLNLS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLS

Mouse                         DLHDLEVLDLSHNAHYFSIAGVTHRLGFIQNLINLRVLNLS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 27 – 1041 Toll-like receptor 8
Topological domain 27 – 827 Extracellular
Repeat 555 – 577 LRR 16
Glycosylation 582 – 582 N-linked (GlcNAc...) asparagine
Glycosylation 590 – 590 N-linked (GlcNAc...) asparagine
Mutagenesis 574 – 574 T -> A. Abolishes responses to both ssRNA and chemical ligands.
Mutagenesis 574 – 574 T -> A. Strongly decreases activation of NF-kappa-B.
Turn 571 – 573



Literature citations
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function.
Aluri J.; Bach A.; Kaviany S.; Chiquetto Paracatu L.; Kitcharoensakkul M.; Walkiewicz M.A.; Putnam C.D.; Shinawi M.; Saucier N.; Rizzi E.M.; Harmon M.T.; Keppel M.P.; Ritter M.; Similuk M.; Kulm E.; Joyce M.; de Jesus A.A.; Goldbach-Mansky R.; Lee Y.S.; Cella M.; Kendall P.L.; Dinauer M.C.; Bednarski J.J.; Bemrich-Stolz C.; Canna S.W.; Abraham S.M.; Demczko M.M.; Powell J.; Jones S.M.; Scurlock A.M.; De Ravin S.S.; Bleesing J.J.; Connelly J.A.; Rao V.K.; Schuettpelz L.G.; Cooper M.A.;
Blood 137:2450-2462(2021)
Cited for: VARIANTS IMD98 LEU-432; LEU-494 AND ASP-572; CHARACTERIZATION OF VARIANTS IMD98 LEU-432; LEU-494 AND ASP-572; INVOLVEMENT IN IMD98; MUTAGENESIS OF ASP-543;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.